Glabridin, an estrogen receptor (ER) agonist, inhibits migration, invasion, and angiogenesis of human breast adenocarcinoma MDA-MB-231 cells by inhibiting the focal adhesion kinase/Rho-associated kinase (FAK/Rho) signaling pathway [15]. The gene discussed is ESR1; the disease is breast adenocarcinoma.